Endogenous erythropoietin in the anemia of chronic disorders

Anemia of Chronic Disease

Volumn , Issue , 2005, Pages 145-200

  Beguin, Yves ^a,b  

^a FUND FOR SCIENTIFIC RESEARCH   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84858268610     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (243)

1. Cartwright GE. The anemia of chronic disorders. Semin Hematol 1966; 3:351-375.
2. Beguin Y. Erythropoietin and the anemia of cancer. Acta Clin Belg 1996; 51:36-52.
3. Means RT Jr, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992; 80:1639-1647.
4. Means RT Jr. Advances in the anemia of chronic disease. Int J Hematol 1999; 70:7-12.
5. Weiss G. Pathogenesis and treatment of anaemia of chronic disease. Blood Rev 2002; 16:87-96.
6. Lee GR. The anemia of chronic disease. Semin Hematol 1983; 20:61-80.
7. Sears D. Anemia of chronic disease. Med Clin North Am 1992; 76:567-579.
8. Torti FM, Torti SV. Cytokines, iron homeostasis, and cancer. Adv Exp Med Biol 1994; 354:161-170.
9. Konijn AM. Iron metabolism in inflammation. Clin Haematol 1994; 7:829-849.
10. Weiss G, Wachter H, Fuchs D. Linkage of cell-mediated immunity to iron metabolism. Immunol Today 1995; 16:495-500.
11. Weiss G. Iron and anemia of chronic disease. Kidney Int Suppl 1999; 69:S12-S17.
12. Means RT Jr. Pathogenesis of the anemia of chronic disease:a cytokine-mediated anemia. Stem Cells 1995; 13:32-37.
13. Trey JE, Kushner I. The acute phase response and the hematopoietic system: the role of cytokines. Crit Rev Oncol Hematol 1995; 21:1-18.
14. Spivak JL. Cancer-related anemia: its causes and characteristics. Semin Oncol 1994; 21(suppl 3):3-8.
15. Moliterno AR, Spivak JL. Anemia of cancer. Hematol Oncol Clin North Am 1996; 10:345-363.
16. Doll DC, Weiss RB. Neoplasia and the erythron. J Clin Oncol 1985; 3:429-446.
17. Tchekmedyian NS. Anemia in cancer patients: significance, epidemiology, and current therapy. Oncology (Huntingt) 2002; 16:17-24.
18. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999; 91:1616-1634.
19. Michon J. Incidence of anemia in pediatric cancer patients in Europe: results of a large, international survey. Med Pediatr Oncol 2002; 39:448-450.
20. Heddens D, Alberts DS, Hannigan EV, Williams SD, Garcia D, Roe DJ, Bell J, Alvarez RD. Prediction of the need for red cell transfusion in newly diagnosed ovarian cancer patients undergoing platinum-based treatment. Gynecol Oncol 2002; 86:239-243.
21. Skillings JR, Sridhar FG, Wong C, Paddock L. The frequency of red cell transfusion for anemia in patients receiving chemotherapy. Am J Clin Oncol 1993; 16:22-25.
22. Benoist S, Panis Y, Pannegeon V, Alves A, Valleur P. Predictive factors for perioperative blood transfusions in rectal resection for cancer: a multivariate analysis of a group of 212 patients. Surgery 2001; 129:433-439.
23. Hensley ML, Lebeau D, Leon LF, Venkatraman E, Waltzman R, Sabbatini P, Almadrones L, Chi D, Spriggs D. Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer. Gynecol Oncol 2001; 81:485-489.
24. Cassidy MJD, De Jager C, Ebrahim O, Camachio P, Robson R. Peripheral blood mononuclear cells from patients with chronic renal failure release factors which suppress erythropoietin secretion in vitro. Nephrol Dial Transplant 1994; 9:775-779.
25. Mara M, Zivny J, Eretova V, Kvasnicka J, Kuzel D, Umlaufova A, Marova E. Changes in markers of anemia and iron metabolism and how they are influenced by antianemics in postpartum period. Acta Obstet Gynecol Scand 2001; 80:142-148.
26. Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992; 79:1987-1994.
27. Vannucchi AM, Grossi A, Rafanelli D, Statello M, Cinotti S, Rossi-Ferrini P. Inhibition of erythropoietin production in vitro by human interferon gamma. Br J Haematol 1994; 87:18-23.
28. Fandrey J, Jelkmann WE. Interleukin-1 and tumor necrosis factor-alpha inhibit erythropoietin production in vitro. Ann N Y Acad Sci 1991; 628:250-255.
29. Jelkmann W, Pagel H, Wolff M, Fandrey J. Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys. Life Sci 1992; 50:301-308.
30. Jelkmann W, Wolff M, Fandrey J. Modulation of the production of erythropoietin by cytokines: in vitro studies and their clinical implications. Contrib Nephrol 1990; 87:68-77.
31. Fandrey J, Huwiler A, Frede S, Pfeilschifter J, Jelkmann W. Distinct signaling pathways mediate phorbol-ester-induced and cytokine-induced inhibition of erythropoietin gene expression. Eur J Biochem 1994; 226:335-340.
32. Jelkmann W, Hellwig-Buergel T. Tumor necrosis factor p55 receptor (TNF-RI) mediates the in vitro inhibition of hepatic erythropoietin production. Exp Hematol 1999; 27:224-228.
33. Hellwig-Burgel T, Rutkowski K, Metzen E, Fandrey J, Jelkmann W. Interleukin-1 beta and tumor necrosis factoralpha stimulate DNA binding of hypoxia-inducible factor-1. Blood 1999; 94:1561-1567.
34. Schobersberger W, Hoffmann G, Fandrey J. Nitric oxide donors suppress erythropoietin production in vitro. Pflugers Arch 1996; 432:980-985.
35. Fandrey J, Frede S, Jelkmann W. Role of hydrogen peroxide in hypoxia-induced erythropoietin production. Biochem J 1994; 303:507-510.
36. Fandrey J, Frede S, Ehleben W, Porwol T, Acker H, Jelkmann W. Cobalt chloride and desferrioxamine antagonize the inhibition of erythropoietin production by reactive oxygen species. Kidney Int 1997; 51:492-496.
37. Jelkmann W, Pagel H, Hellwig T, Fandrey J. Effects of antioxidant vitamins on renal and hepatic erythropoietin production. Kidney Int 1997; 51:497-501.
38. Leng HM, Kidson SH, Keraan MM, Randall GW, Folb PI. Cytokine-mediated inhibition of erythropoietin synthesis by dexamethasone. J Pharm Pharmacol 1996; 48:971-974.
39. Frede S, Fandrey J, Pagel H, Hellwig T, Jelkmann W. Erythropoietin gene expression is suppressed after lipopolysaccharide or interleukin-1 beta injections in rats. Am J Physiol 1997; 273:R1067-R1071.
40. Chuncharunee S, Carter CD, Studtmann KE, Caro J, Coffey RJ, Dessypris EN. Chronic administration of transforming growth factor-beta suppresses erythropoietindependent erythropoiesis and induces tumour necrosis factor in vivo. Br J Haematol 1993; 84:374-380.
41. Miller KL, Carlino JA, Ogawa Y, Avis PD, Carroll KG. Alterations in erythropoiesis in TGF-beta 1-treated mice. Exp Hematol 1992; 20:951-956.
42. Nieken J, Mulder NH, Buter J, Vellenga E, Limburg PC, Piers DA, de Vries EG. Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. Blood 1995; 86:900-905.
43. Oczko-Grzesik B, Wiecek A, Kokot F. Influence of IFN-alpha on plasma erythropoietin levels in patients with hepatitis B virus-associated chronic active hepatitis. J Interferon Cytokine Res 2001; 21:669-676.
44. Johnson CS, Keckler DJ, Topper MI, Braunschweiger PG, Furmanski P. In vivo hematopoietic effects of recombinant interleukin-1 alpha in mice: stimulation of granulocytic, monocytic, megakaryocytic, and early erythroid progenitors, suppression of late-stage erythropoiesis, and reversal of erythroid suppression with erythropoietin. Blood 1989; 73:678-683.
45. Furmanski P, Johnson CS. Macrophage control of normal and leukemic erythropoiesis: identification of the macrophagederived erythroid suppressing activity as interleukin-1 and the mediator of its in vivo action as tumor necrosis factor. Blood 1990; 75:2328-2334.
46. de Haan G, Dontje B, Loeffler M, Nijhof W. Microenvironmentally dependent effects on murine haematopoiesis by a prolonged interleukin-1 treatment. Br J Haematol 1993; 85:15-19.
47. Johnson CS, Cook CA, Furmanski P. In vivo suppression of erythropoiesis by tumor necrosis factor-alpha (TNF-alpha):reversal with exogenous erythropoietin (EPO). Exp Hematol 1990; 18:109-113.
48. Clibon U, Bonewald L, Caro J, Roodman GD. Erythropoietin fails to reverse the anemia in mice continuously exposed to tumor necrosis factor-alpha in vivo. Exp Hematol 1990; 18:438-441.
49. Roodman GD, Johnson RA, Clibon U. Tumor necrosis factor alpha and the anemia of chronic disease: effects of chronic exposure to TNF on erythropoiesis in vivo. Adv Exp Med Biol 1989; 271:185-196.
50. Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev 1992; 72:449-489.
51. Barosi G. Inadequate erythropoietin response to anemia: definition and clinical relevance. Ann Hematol 1994; 68:215-223.
52. Bozzini CE, Alippi RM, Barcelo AC. Enhanced effect of increased erythrocyte production rate on plasma erythropoietin levels of mice during subsequent exposure to hypobaria. Adv Exp Med Biol 1989; 271:23-27.
53. Alippi RM, Boyer P, Leal T, Barcelo AC, Martinez MP, Bozzini CE. Higher erythropoietin secretion in response to cobaltous chloride in post-hypoxic than in hypertransfused polycythemic mice. Haematologica 1992; 77:446-449.
54. Alippi RM, Barcelo AC, Bozzini CE. Enhanced erythropoiesis induced by hypoxia in hypertransfused, post-hypoxic mice. Exp Hematol 1983; 11:878-883.
55. Alippi RM, Barcelo AC, Bozzini CE. Erythropoietic response to hypoxia in mice with polycythemia induced by hypoxia or transfusion. Exp Hematol 1983; 11:122-128.
56. Alippi RM, Barcelo AC, Bozzini CE. Comparison of erythropoietic response to erythropoietin-secreting stimuli in mice following polycythemia induced by transfusion or hypoxia. Exp Hematol 1985; 13:159-162.
57. Alippi RM, Barcelo AC, Kofoed JA, Bozzini CE. Hypoxiainduced renal and extrarenal erythropoietin production in posthypoxic or hypertransfused polycythemic rats. Exp Hematol 1986; 14:329-332.
58. Erslev AJ. Erythropoietin. N Engl J Med 1991; 324:1339-1344.
59. Garcia JF, Ebbe SN, Hollander L, Cutting HO, Miller MO, Cronkite EP. Radioimmunoassay of erythropoietin: circulating levels in normal and polycythemic human beings. J Lab Clin Med 1982; 99:624-635.
60. Caro J, Brown S, Miller O, Murray T, Erslev AJ. Erythropoietin levels in uremic nephric and anephric patients. J Lab Clin Med 1979; 93:449-458.
61. Cotes PM, Doré CJ, Liu Yin JA, Lewis SM, Messinezy M, Pearson TC, Reid C. Determination of serum immunoreactive erythropoietin in the investigation of erythrocytosis. N Engl J Med 1986; 315:283-287.
62. Beguin Y, Clemons G, Pootrakul P, Fillet G. Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood 1993; 81:1067-1076.
63. Beguin Y, Yerna M, Loo M, Weber M, Fillet G. Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production. Br J Haematol 1992; 82:648-653.
64. Alexanian R. Erythropoietin excretion in bone marrow failure and hemolytic anemia. J Lab Clin Med 1973; 82:438-445.
65. Bray GL, Taylor B, O’Donnell R. Comparison of the erythropoietin response in children with aplastic anemia, transient erythroblastopenia, and iron deficiency. J Pediatr 1992; 120:528-532.
66. Schrezenmeier H, Noe G, Raghavachar A, Rich IN, Heimpel H, Kubanek B. Serum erythropoietin and serum transferrin receptor levels in aplastic anaemia. Br J Haematol 1994; 88:286-294.
67. de Klerk G, Rosengarten PCJ, Vet RJWM, Goudsmit R. Serum erythropoietin (ESF) titers in anemia. Blood 1981; 58:1164-1170.
68. Urabe A, Mitani K, Yoshinaga K, Iki S, Yagisawa M, Ohbayashi Y, Takaku F. Serum erythropoietin titers in hematologi- cal malignancies and related diseases. Int J Cell Cloning 1992; 10:333-337.
69. Gaines Das RE, Milne A, Rowley M, Smith EC, Cotes PM. Serum immunoreactive erythropoietin in patients with idiopathic aplastic and Fanconi’s anaemias. Br J Haematol 1992; 82:601-607.
70. Cazzola M, Guarnone R, Cerani P, Centenara E, Rovati A, Beguin Y. Red blood cell precursor mass as an independent determinant of serum erythropoietin level. Blood 1998; 91:2139-2145.
71. Piroso E, Erslev AJ, Caro J. Inappropriate increase in erythropoietin titers during chemotherapy. AmJHematol 1989; 32:248-254.
72. Birgegard G, Wide L, Simonsson B. Marked erythropoietin increase before fall in Hb after treatment with cytostatic drugs suggests mechanism other than anaemia for stimulation. Br J Haematol 1989; 72:462-466.
73. Schapira L, Antin JH, Ransil BJ, Antman KH, Eder JP, McGarigle CJ, Goldberg MA. Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy. Blood 1990; 76:2354-2359.
74. Beguin Y, Clemons GK, Oris R, Fillet G. Circulating erythropoietin levels after bone marrow transplantation: inappropriate response to anemia in allogeneic transplants. Blood 1991; 77:868-873.
75. Beguin Y, Oris R, Fillet G. Dynamics of erythropoietic recovery after bone marrow transplantation: role of marrow proliferative capacity and erythropoietin production in autologous versus allogeneic transplants. Bone Marrow Transplant 1993; 11:285-292.
76. Beguin Y, Baron F, Fillet G. Influence of marrow erythropoietic activity on serum erythropoietin levels after autologous hematopoietic stem cell transplantation. Haematologica 1998; 83:1076-1081.
77. Kendall RG, Cavill I, Norfolk DR. Erythropoietin consumption during stimulated erythropoiesis. Ann N Y Acad Sci 1994; 718:350-352.
78. Finne PH, Skoglund R, Wetterhus S. Urinary erythropoietin excretion during initial treatment of pernicious anaemia. Scand J Haematol 1973; 10:62-68.
79. Kendall RG, Cavill I, Norfolk DR. Serum erythropoietin levels during haematinic therapy. Br J Haematol 1992; 81:630-631.
80. Youssoufian H, Longmore G, Neumann D, Yoshimura A, Lodish HF. Structure, function, and activation of the erythropoietin receptor. Blood 1993; 81:2223-2236.
81. Bowen DT, Janowska-Wieczorek A. Serum erythropoietin following cytostatic therapy [letter]. Br J Haematol 1990; 74:372-373.
82. Stohlman F Jr, Brecher G. Humoral regulation of erythropoiesis. Relationship of plasma erythropoietin level to bone marrow activity. Proc Soc Exp Biol Med 1959; 100:40-43.
83. Naets JP, Wittek M. Effect of erythroid hypoplasia on utilization of erythropoietin. Nature 1965; 206:726-727.
84. Bozzini CE. Influence of erythroid activity of the bone marrow on the plasma disappearance of injected erythropoietin in dogs. Nature 1966; 209:1140-1141.
85. Steinberg SE, Garcia JF, Matzke GR, Mladenovic J. Erythropoietin kinetics in rats: generation and clearance. Blood 1986; 67:646-649.
86. Widness JA, Veng-Pedersen P, Schmidt RL, Lowe LS, Kisthard JA, Peters C. In vivo 125I-erythropoietin pharmacokinetics are unchanged after anesthesia, nephrectomy and hepatectomy in sheep. J Pharmacol Exp Ther 1996; 279:1205-1210.
87. Spivak JL, Hogans BB. The in vivo metabolism of recombinant human erythropoietin in the rat. Blood 1989; 73:90-99.
88. Spivak JL. Metabolism of recombinant human erythropoietin in the rat. Adv Exp Med Biol 1989; 271:29-38.
89. Piroso E, Erslev AJ, Flaharty KK, Caro J. Erythropoietin life span in rats with hypoplastic and hyperplastic bone marrows. Am J Hematol 1991; 36:105-110.
90. Lezon CE, Martinez MP, Conti MI, Bozzini CE. Plasma disappearance of exogenous erythropoietin in mice under different experimental conditions. Endocrine 1998; 8:331-333.
91. Flaharty KK, Caro J, Erslev A, Whalen JJ, Morris EM, Bjornsson TD, Vlasses PH. Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. Clin Pharmacol Ther 1990; 47:557-564.
92. Cheung WK, Goon BL, Guilfoyle MC, Wacholtz MC. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin Pharmacol Ther 1998; 64:412-423.
93. Kato M, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y. Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. J Pharmacol Exp Ther 1997; 283:520-527.
94. Chapel SH, Veng-Pedersen P, Schmidt RL, Widness JA. Receptor-based model accounts for phlebotomy-induced changes in erythropoietin pharmacokinetics. Exp Hematol 2001; 29:425-431.
95. Kampf D, Eckardt KU, Fischer HC, Schmalisch C, Ehmer B, Schostak M. Pharmacokinetics of recombinant human erythropoietin in dialysis patients after single and multiple subcutaneous administrations. Nephron 1992; 61:393-398.
96. McMahon FG, Vargas R, Ryan M, Jain AK, Abels RI, Perry B, Smith IL. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 1990; 76:1718-1722.
97. Sans T, Joven J, Vilella E, Masdeu G, Farre M. Pharmacokinetics of several subcutaneous doses of erythropoietin:potential implications for blood transfusion. Clin Exp Pharmacol Physiol 2000; 27:179-184.
98. Kinoshita H, Ohishi N, Kato M, Tokura S, Okazaki A. Distribution of recombinant human erythropoietin following multiple intravenous administration and effects of age on the distribution in rats. Arzneimittelforschung 1992; 42:579-584.
99. Chapel S, Veng-Pedersen P, Hohl RJ, Schmidt RL, McGuire EM, Widness JA. Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway. J Pharmacol Exp Ther 2001; 298:820-824.
100. Piron M, Loo M, Gothot A, Tassin F, Fillet G, Beguin Y. Cessation of intensive treatment with recombinant human erythropoietin is followed by secondary anemia. Blood 2001; 97:442-448.
101. Bozzini CE, Alippi RM, Barcelo AC, Conti MI, Bozzini C, Lezon CE, Olivera MI. The biology of stress erythropoiesis and erythropoietin production. Ann N Y Acad Sci 1994; 718:83-92.
102. Lezon C, Alippi RM, Barcelo AC, Martinez MP, Conti MI, Bozzini CE. Depression of stimulated erythropoietin production in mice with enhanced erythropoiesis. Haematologica 1995; 80:491-494.
103. Bozzini CE, Barcelo AC, Conti MI, Martinez MP, Lezon CE, Bozzini C, Alippi RM. Unexpected hypoxia-dependent erythropoietin secretion during experimental conditions not affecting tissue oxygen supply=demand ratio. Kidney Int 1997; 51:413-415.
104. Barcelo AC, Bozzini CE. Erythropoietin formation during hypoxia in mice with impaired responsiveness to erythropoietin induced by irradiation or 5-fluorouracil injection. Experientia 1982; 38:504-505.
105. Bergamaschi G, Recalde HH, Ponchio L, Rosti V, Cazzola M. Erythrophagocytosis increases the expression of erythroid potentiating activity mRNA in human monocyte-macrophages. Exp Hematol 1993; 21:70-73.
106. Erslev AJ. The effect of hemolysates on red cell production and erythropoietin release. J Lab Clin Med 1971; 78:1-7.
107. Means RT Jr. Cytokines and anaemia in human immunodeficiency virus infection. Cytokines Cell Mol Ther 1997; 3:179-186.
108. Moyle G. Anaemia in persons with HIV infection: prognostic marker and contributor to morbidity. AIDS Rev 2002; 4:13-20.
109. Calenda V, Chermann JC. Severe in vitro inhibition of erythropoiesis and transient stimulation of granulopoiesis after bone-marrow infection with eight different HIV-2 isolates. AIDS 1992; 6:943-948.
110. Reddy MM, Grieco MH. Erythropoietin and granulocytemacrophage colony-stimulating factor (GM-CSF) levels in sera of patients with HIV infection. Int J STD AIDS 1991; 2:128-132.
111. Allen UD, King SM, Gomez MP, Lapointe N, Forbes JC, Thorne A, Kirby MA, Bowker J, Raboud J, Singer J, Mukwaya G, Tobin J, Read SE. Serum immunoreactive erythropoietin levels and associated factors amongst HIV-infected children. AIDS 1998; 12:1785-1791.
112. Semba RD, Broadhead R, Taha TE, Totin D, Ricks MO, Kumwenda N. Erythropoietin response to anemia among human immunodeficiency virus-infected infants in Malawi. Haematologica 2001; 86:1221-1222.
113. Rarick MU, Loureiro C, Groshen S, Sullivan Halley J, Gill PS, Bernstein Singer M, Levine AM. Serum erythropoietin titers in patients with human immunodeficiency virus (HIV) infection and anemia. J Acquir Immune Defic Syndr 1991; 4:593-597.
114. Kreuzer KA, Rockstroh JK, Jelkmann W, Theisen A, Spengler U, Sauerbruch T. Inadequate erythropoietin response to anaemia in HIV patients: relationship to serum levels of tumour necrosis factor-alpha, interleukin-6 and their soluble receptors. Br J Haematol 1997; 96:235-239.
115. Spivak JL, Barnes DC, Fuchs E, Quinn TC. Serum immunoreactive erythropoietin in HIV-infected patients. JAMA 1989; 261:3104-3107.
116. Camacho J, Poveda F, Zamorano AF, Valencia ME, Vazquez JJ, Arnalich F. Serum erythropoietin levels in anaemic patients with advanced human immunodeficiency virus infection. Br J Haematol 1992; 82:608-614.
117. Walker RE, Parker RI, Kovacs JA, Masur H, Lane HC, Carleton S, Kirk LE, Gralnik HR, Fauci AS. Anemia and erythropoiesis in patients with the acquired immunodeficiency syndrome (AIDS) and Kaposi sarcoma treated with zidovudine. Ann Intern Med 1988; 108:372-376.
118. Bertero MT, Caligaris-Cappio F. Anemia of chronic disorders in systemic autoimmune diseases. Haematologica 1997; 82:375-381.
119. Vreugdenhil G, Swaak AJ. The role of erythropoietin in the anaemia of chronic disease in rheumatoid arthritis. Clin Rheumatol 1990; 9:22-27.
120. Graudal N, Nielsen OJ, Galloe AM, Graudal HN. The course of erythropoietin in patients with rheumatoid arthritis with normal and low blood-hemoglobin. A longitudinal study. Scand J Rheumatol 1993; 22:86-89.
121. Chijiwa T, Nishiya K, Hashimoto K. Serum transferrin receptor levels in patients with rheumatoid arthritis are correlated with indicators for anaemia. Clin Rheumatol 2001; 20:307-313.
122. Vreugdenhil G, Wognum AW, van Eijk HG, Swaak AJ. Anaemia in rheumatoid arthritis: the role of iron, vitamin B12, and folic acid deficiency, and erythropoietin responsiveness. Ann Rheum Dis 1990; 49:93-98.
123. Giordano N, Cecconami L, Marcucci P, Battisti E, Magaro L, Morozzi G, Mariano A, Marcolongo R. The role of iron, vitamin B12, folic acid and erythropoietin in the anemia of rheumatoid arthritis. Clin Exp Rheumatol 1992; 10:201-202.
124. Takashina N, Kondo H, Kashiwazaki S. Suppressed serum erythropoietin response to anemia and the efficacy of recombinant erythropoietin in the anemia of rheumatoid arthritis. J Rheumatol 1990; 17:885-887.
125. Remacha AF, Rodriguez de la Serna A, Garcia Die F, Geli C, Diaz C, Gimferrer E. Erythroid abnormalities in rheumatoid arthritis: the role of erythropoietin. J Rheumatol 1992; 19:1687-1691.
126. Nielsen OJ, Andersen LS, Ludwigsen E, Bouchelouche P, Hansen TM, Birgens H, Hansen NE. Anaemia of rheumatoid arthritis: serum erythropoietin concentrations and red cell distribution width in relation to iron status. Ann Rheum Dis 1990; 49:349-353.
127. Hochberg MC, Arnold CM, Hogans BB, Spivak JL. Serum immunoreactive erythropoietin in rheumatoid arthritis:impaired response to anemia. Arthritis Rheum 1988; 31:1318-1321.
128. Noe G, Augustin J, Hausdorf S, Rich IN, Kubanek B. Serum erythropoietin and transferrin receptor levels in patients with rheumatoid arthritis. Clin Exp Rheumatol 1995; 13:445-451.
129. Boyd HK, Lappin TR, Bell AL. Evidence for impaired erythropoietin response to anaemia in rheumatoid disease. Br J Rheumatol 1991; 30:255-259.
130. Boyd HK, Lappin TR. Erythropoietin deficiency in the anaemia of chronic disorders. Eur J Haematol 1991; 46:198-201.
131. Baer AN, Dessypris EN, Goldwasser E, Krantz SB. Blunted erythropoietin response to anaemia in rheumatoid arthritis. Br J Haematol 1987; 66:559-564.
132. Cazzola M, Ponchio L, de Benedetti F, Ravelli A, Rosti V, Beguin Y, Invernizzi R, Barosi G, Martini A. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemiconset juvenile chronic arthritis. Blood 1996; 87:4824-4830.
133. Kirel B, Yetgin S, Saatci U, Ozen S, Bakkaloglu A, Besbas N. Anaemia in juvenile chronic arthritis. Clin Rheumatol 1996; 15:236-241.
134. Fantini F, Gattinara M, Gerloni V, Bergomi P, Cirla E. Severe anemia associated with active systemic-onset juvenile rheumatoid arthritis successfully treated with recombinant human erythropoietin:a pilot study. Arthritis Rheum 1992; 35:724-726.
135. Martini A, Ravelli A, Di Fuccia G, Rosti V, Cazzola M, Barosi G. Intravenous iron therapy for severe anaemia in systemic-onset juvenile chronic arthritis. Lancet 1994; 344:1052-1054.
136. Cimmino MA, Parisi M, Querci G, Ghio R, Accardo S. Intravenous iron is effective in treating the anaemia of rheumatoid arthritis and is not associated with flares of synovitis [letter]. Clin Rheumatol 1997; 16:215-216.
137. Davis D, Charles PJ, Potter A, Feldmann M, Maini RN, Elliott MJ. Anaemia of chronic disease in rheumatoid arthritis:in vivo effects of tumour necrosis factor alpha blockade. Br J Rheumatol 1997; 36:950-956.
138. Zucker S, Lysik R. Bone marrow erythropoiesis in anemia of inflammation. J Lab Clin Med 1974; 84:620-631.
139. DeGowin RL, Gibson DP. Erythropoietin and the anemia of mice bearing extramedullary tumor. J Lab Clin Med 1979; 94:303-311.
140. Dainiak N, Kulkarni V, Howard D, Kalmanti M, Dewey MC, Hoffman R. Mechanisms of abnormal erythropoiesis in malignancy. Cancer 1983; 51:1101-1106.
141. Ward HP, Kurnick JE, Pisarczyk MJ. Serum level of erythropoietin in anemias associated with chronic infection, malignancy, and primary hematopoietic disease. J Clin Invest 1971; 50:332-335.
142. Cox R, Musial T, Gyde OH. Reduced erythropoietin levels as a cause of anaemia in patients with lung cancer. Eur J Cancer Clin Oncol 1986; 22:511-514.
143. Zarrabi MH, Lysik R, DiStefano J, Zucker S. The anaemia of chronic disorders: studies of iron reutilization in the anaemia of experimental malignancy and chronic inflammation. Br J Haematol 1977; 35:647-658.
144. Zucker S, Friedman S, Lysik RM. Bone marrow erythropoiesis in the anemia of infection, inflammation, and malignancy. J Clin Invest 1974; 53:1132-1138.
145. Lockner D. Iron absorption and serum erythropoietin concentration in patients with cancer of the uterine cervix. Acta Med Scand 1966; 180:651-655.
146. Nseyo UO, Williams PD, Murphy GP. Clinical significance of erythropoietin levels in renal carcinoma. Urology 1986; 28:301-306.
147. Schreuder WO, Ting WC, Smith S, Jacobs A. Testosterone, erythropoietin and anaemia in patients with disseminated bronchial cancer. Br J Haematol 1984; 57:521-526.
148. Erslev AJ, Wilson J, Caro J. Erythropoietin titers in anemic, nonuremic patients. J Lab Clin Med 1987; 109:429-433.
149. Leng HM, Albrecht CF, Kidson SH, Folb PI. Erythropoietin production in anemia associated with experimental cancer. Exp Hematol 1999; 27:806-810.
150. Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990; 322:1689-1692.
151. Ponchio L, Beguin Y, Farina G, Pedrazzoli P, Pedrotti C, Poggi G, Rosti V, Bergamaschi G, Battistel V, Cazzola M. Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia. Haematologica 1992; 77:494-501.
152. Abels RI. Recombinant human erythropoietin in the treatment of the anaemia of cancer. ActaHaematol 1992; 87(suppl 1):4-11.
153. Abels RI. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Semin Oncol 1992; 19:29-35.
154. Cascinu S, Fedeli A, Del Ferro E, Luzi Fedeli S, Catalano G. Recombinant human erythropoietin treatment in cisplatinassociated anemia: a randomized, double-blind trial with placebo. J Clin Oncol 1994; 12:1058-1062.
155. Osterborg A, Boogaerts MA, Cimino R, Essers U, Holowiecki J, Juliusson G, Jager G, Najman A, Peest D. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin’s lymphoma. A randomized multicenter study. Blood 1996; 87:2675-2682.
156. Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegler L, Essers U, Greil R, Grossi A, Jager G, LeMevel A, Najman A, Silingardi V, Spriano M, van Hoof A, Ehmer B. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin’s lymphoma: dose finding and identification of predictors of response. Blood 1995; 86:4446-4453.
157. Platanias LC, Miller CB, Mick R, Hart RD, Ozer H, McEvilly JM, Jones RJ, Ratain MJ. Treatment of chemotherapy- induced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol 1991; 9:2021-2026.
158. Cazzola M, Ponchio L, Beguin Y, Rosti V, Bergamaschi G, Liberato NL, Fregoni V, Nalli G, Barosi G, Ascari E. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I=II clinical trial. Blood 1992; 79:29-37.
159. Oster W, Herrmann F, Gamm H, Zeile G, Lindemann A, Muller G, Brune T, Kraemer HP, Mertelsmann R. Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J Clin Oncol 1990; 8:956-962.
160. Kettelhack C, Schoter D, Matthias D, Schlag PM. Serum erythropoietin levels in patients with solid tumours. Eur J Cancer 1994; 30A:1289-1291.
161. Kalmanti M, Kalmantis T. Committed erythroid progenitors and erythropoietin levels in anemic children with lymphomas and tumors. Pediatr Hematol Oncol 1989; 6:85-93.
162. Chudek J, Wiecek A, Kokot F, Grochal A, Switala J, Kanwiszer J. Serum erythropoietin concentration in women with uterine or ovarian tumors. Przegl Lek 1998; 55:47-50.
163. Dowlati A, R’Zik S, Fillet G, Beguin Y. Anaemia of lung cancer is due to impaired erythroid marrow response to erythropoietin stimulation as well as relative inadequacy of erythropoietin production. Br J Haematol 1997; 97:297-299.
164. Lee SJ, Kwon JH, Jung CW. Erythropoietin response is inadequate in cancer patients receiving chemotherapy. Int J Hematol 2001; 74:416-420.
165. Corazza F, Beguin Y, Bergmann P, Andre M, Ferster A, Devalck C, Fondu P, Buyse M, Sariban E. Anemia in children with cancer is associated with decreased erythropoietic activity and not with inadequate erythropoietin production. Blood 1998; 92:1793-1798.
166. Sawabe Y, Iida S, Tabata Y, Yonemitsu H. Serum erythropoietin measurements by a one-step sandwich enzyme linked immunosorbent assay in patients with hepatocellular carcinoma and liver cirrhosis. Jpn J Clin Oncol 1993; 23:273-277.
167. Malaguarnera M, Bentivegna P, Di Fazio I, Laurino A, Romano M, Trovato BA. Erythropoietin in hepatocellular carcinoma. Bull Cancer 1996; 83:977-980.
168. Vadhan-Raj S, Hittelman WN, Lepe-Zuniga JL, Gutterman JU, Broxmeyer HE. Regulation of endogenous erythropoietin levels in anemia associated with myelodysplastic syndromes [letter]. Blood 1990; 75:1749-1750.
169. Verhoef GE, De Schouwer P, Ceuppens JL, Van Damme J, Goossens W, Boogaerts MA. Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia 1992; 6:1268-1272.
170. Jacobs A, Janowska-Wieczorek A, Caro J, Bowen DT, Lewis T. Circulating erythropoietin in patients with myelodysplastic syndromes. Br J Haematol 1989; 73:36-39.
171. Bowen DT, Jacobs A, Cotes PM, Lewis TC. Serum erythropoietin and erythropoiesis in patients with myelodysplastic syndromes. Eur J Haematol 1990; 44:30-32.
172. Bowen DT, Culligan D, Beguin Y, Kendall R, Willis N. Estimation of effective and total erythropoiesis in myelodysplasia using serum transferrin receptor and erythropoietin concentrations, with automated reticulocyte parameters. Leukemia 1994; 8:151-155.
173. Pasqualetti P, Collacciani A, Casale R. Circadian rhythm of serum erythropoietin in myelodysplastic syndromes. Eur Rev Med Pharmacol Sci 2000; 4:111-115.
174. Wallvik J, Stenke L, Bernell P, Nordahl G, Hippe E, Hast R. Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes. Eur J Haematol 2002; 68:180-185.
175. Piedras J, Hernandez G, Lopez-Karpovitch X. Effect of androgen therapy and anemia on serum erythropoietin levels in patients with aplastic anemia and myelodysplastic syndromes. Am J Hematol 1998; 57:113-118.
176. McMullin MF, Hillmen P, Elder GE, Lappin TR, Luzzatto L. Serum erythropoietin levels in paroxysmal nocturnal haemo- globinuria: implications for therapy [see comments]. Br J Haematol 1996; 92:815-817.
177. Nakakuma H, Nagakura S, Kawaguchi T, Horikawa K, Iwamoto N, Kagimoto T, Takatsuki K. Markedly high plasma erythropoietin and granulocyte-colony stimulating factor levels in patients with paroxysmal nocturnal hemoglobinuria. Int J Hematol 1997; 66:451-457.
178. Barosi G, Liberato LN, Guarnone R. Serum erythropoietin in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 1993; 83:365-369.
179. Najean Y, Schlageter MH, Toubert ME, Rain JD. Erythropoietin concentration in the serum from patients with primary thrombocythaemia [letter]. Eur J Haematol 1995; 55:272-273.
180. Andreasson B, Lindstedt G, Kutti J. Plasma erythropoietin in essential thrombocythaemia: at diagnosis and in response to myelosuppressive treatment. Leuk Lymphoma 2000; 38:113-120.
181. Messinezy M, Westwood NB, El Hemaidi I, Marsden JT, Sherwood RS, Pearson TC. Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia. Br J Haematol 2002; 117:47-53.
182. Griesshammer M, Kubanek B, Beneke H, Heimpel H, Bangerter M, Bergmann L, Schrezenmeier H. Serum erythropoietin and thrombopoietin levels in patients with essential thrombocythaemia. Leuk Lymphoma 2000; 36:533-538.
183. Jansen JH, Wientjens GJ, Fibbe WE, Ralph P, Van Damme J, den Ottolander GJ, Willemze R, Kluin Nelemans JC. Serum monocyte colony-stimulating factor, erythropoietin and interleukin-6 in relation to pancytopenia in hairy cell leukemia. Leukemia 1992; 6:735-737.
184. Mauro FR, Gentile M, Foa R. Erythropoietin and chronic lymphocytic leukemia. Rev Clin Exp Hematol Suppl 2002; 1:21-31.
185. Beguin Y, Lampertz S, Bron D, Fillet G. Serum erythropoietin in chronic lymphocytic leukemia. Br J Haematol 1996; 93:154-156.
186. Johannsen H, Jelkmann W, Wiedemann G, Otte M, Wagner T. Erythropoietin=haemoglobin relationship in leukaemia and ulcerative colitis. Eur J Haematol 1989; 43:201-206.
187. Jelkmann W, Johannsen H, Wiedemann G, Otte M, Wagner T. Dependence of serum erythropoietin level on erythropoiesis in leukemia. Hamatol Bluttransfus 1990; 33:83-86.
188. Jelkmann W, Wiedemann G. High serum immunoreactive erythropoietin in leukaemic patients with bone marrow insufficiency of erythropoiesis [letter]. Eur J Haematol 1990; 45:271-272.
189. Hellebostad M, Marstrander J, Slrdahl SH, Cotes PM, Refsum HE. Serum immunoreactive erythropoietin in children with acute leukaemia at various stages of disease- and the effects of treatment. Eur J Haematol 1990; 44:159-164.
190. Kivivuori SM, Viinikka L, Teppo AM, Siimes MA. Serum transferrin receptor and erythropoiesis in children with newly diagnosed acute lymphoblastic leukemia. Leuk Res 1994; 18:823-828.
191. Pohl C, Schobert I, Moter A, Woll EM, Schwonzen M, Hiersche A, Diehl V. Serum erythropoietin levels in patients with Hodgkin’s lymphoma at the time of diagnosis. Ann Oncol 1992; 3:172-173.
192. Beguin Y. Erythropoiesis and erythropoietin in multiple myeloma. Leuk Lymphoma 1995; 18:413-421.
193. Paaske Hansen O, Drivsholm A. Interrelationships between blood volume, venous hematocrit and renal failure in myelomatosis. Scand J Haematol 1978; 20:461-466.
194. Birgens HS, Paaske Hansen O, Henriksen JH, Wantzin P. Quantitation of erythropoiesis in myelomatosis. Scand J Haematol 1979; 22:357-363.
195. Nielsen OJ, Brandt M, Drivsholm A. The secretory erythropoietin response in patients with multiple myeloma and Waldenstrom’s macroglobulinaemia. Scand J Clin Lab Invest 1990; 50:697-703.
196. Majumdar G, Westwood NB, Bell-Witter C, Muggleston D, Phillips J, Pearson TC. Serum erythropoietin and circulating BFU-E in patients with multiple myeloma and anaemia but without renal failure. Leuk Lymphoma 1993; 9:173-176.
197. Ariad S, Clifford D, Penfold G, MacPhail AP, Bezwoda WR. Erythropoietin response in anaemic patients with multiple myeloma and other lymphoid malignancies infiltrating the bone marrow. Eur J Haematol 1992; 49:59-62.
198. Paaske Hansen O, Thorling EB, Drivsholm A. Serum erythropoietin in myelomatosis. Scand J Haematol 1977; 19:106-110.
199. Singh A, Eckardt KU, Zimmermann A, Gotz KH, Hamann M, Ratcliffe PJ, Kurtz A, Reinhart WH. Increased plasma viscosity as a reason for inappropriate erythropoietin formation. J Clin Invest 1993; 91:251-256.
200. Host H, Skjaelaaen P. Comparative effects of cyclophosphamide and total body irradiation on erythropoietin production in rats. Scand J Haematol 1966; 3:154-157.
201. McDonald TP, Lange RD, Congdon CC, Toya RE. Effect of hypoxia, irradiation, and bone marrow transplantation on erythropoietin levels in mice. Radiat Res 1970; 42:151-163.
202. Magid E, Hansen P. The erythropoietin content of plasma from sheep treated with nitrogen mustard. Scand J Clin Lab Invest 1966; 18:347-352.
203. Chakraborty A, Chatterjee M. Enhanced erythropoietin and suppression of gamma-glutamyl transpeptidase (ggt) activity in murine lymphoma following administration of vanadium. Neoplasma 1994; 41:291-296.
204. Fisher JW, Roh BL. Influence of alkylating agents on kidney erythropoietin production. Cancer Res 1964; 24:983-988.
205. Wolff M, Jelkmann W. Effects of chemotherapeutic and immunosuppressive drugs on the production of erythropoietin in human hepatoma cultures. Ann Hematol 1993; 66:27-31.
206. Jelkmann W, Wolff M, Fandrey J. Inhibition of erythropoietin production by cytokines and chemotherapy may contribute to the anemia in malignant diseases. Adv Exp Med Biol 1994; 345:525-530.
207. Von Hoff DD, Schilsky R, Reichert CM, Reddick RL, Rozencweig M, Young RC, Muggia FM. Toxic effects of cisdichlorodiammineplatinum(II) in man. Cancer Treat Rep 1979; 63:1527-1531.
208. Horiguchi H, Kayama F, Oguma E, Willmore WG, Hradecky P, Bunn HF. Cadmium and platinum suppression of erythropoietin production in cell culture: clinical implications. Blood 2000; 96:3743-3747.
209. Rothman SA, Paul P, Weick JK, McIntyre WR, Fantelli F. Effect of cis-diamminedichloroplatinum on erythropoietin production and hematopoietic progenitor cells. Int J Cell Cloning 1985; 3:415-423.
210. Unami A, Nishina N, Terai T, Sato S, Tamura T, Noda K, Mine Y. Effects of cisplatin on erythropoietin production in rats. J Toxicol Sci 1996; 21:157-165.
211. Vaziri ND, Zhou XJ, Liao SY. Erythropoietin enhances recovery from cisplatin-induced acute renal failure. Am J Physiol 1994; 266:F360-F366.
212. Baldwin MD, Zhou XJ, Ing TS, Vaziri ND. Erythropoietin ameliorates anemia of cisplatin induced acute renal failure. ASAIO J 1998; 44:44-47.
213. Matsumoto T, Endoh K, Kamisango K, Akamatsu K, Koizumi K, Higuchi M, Imai N, Mitsui H, Kawaguchi T. Effect of recombinant human erythropoietin on anticancer druginduced anaemia. Br J Haematol 1990; 75:463-468.
214. Wood PA, Hrushesky WJ. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest 1995; 95:1650-1659.
215. Sawabe Y, Kikuno K, Iseki T, Lida S, Tabata Y, Yonemitsu H. Changes in serum erythropoietin and the reticulocyte count during chemotherapy for leukemias. Eur J Haematol 1996; 57:384-388.
216. Sawabe Y, Kikuno K, Iseki T, Iida S, Yonemitsu H. Serum erythropoietin values and serum iron status during chemotherapy for leukemia. Eur J Haematol 1998; 60:315-316.
217. Sawabe Y, Takiguchi Y, Kikuno K, Iseki T, Ito J, Iida S, Kuriyama T, Yonemitsu H. Changes in levels of serum erythropoietin, serum iron and unsaturated iron binding capacity during chemotherapy for lung cancer. Jpn J Clin Oncol 1998; 28:182-186.
218. Cerruti A, Castello G, Balleari E, Bogliolo G, Lerza R, Pannacciuli I. Serum erythropoietin increase in patients receiving adjuvant therapy with 5-fluorouracil and leucovorin. Exp Hematol 1994; 22:1261-1263.
219. Miranda CE, Scaro JL, Buys MC, Torrejon I, Martin B, Guerra L. Urinary elimination of erythropoietin in patients under treatment with cytostatics drugs. Acta Physiol Pharmacol Ther Latinoam 1998; 48:207-210.
220. Kinjo K, Kizaki M, Takayama N, Michikawa N, Oda A, Okamoto S, Tahara T, Kato T, Miyazaki H, Ikeda Y. Serum thrombopoietin and erythropoietin levels in patients with acute promyelocytic leukaemia during all-trans retinoic acid treatment. Br J Haematol 1999; 105:382-387.
221. Franek E, Marcinkowski W, Kokot F, Wiecek A, Nowicki M. A single dose of cyclophosphamide (Cph) does increase erythropoietin concentration in patients with hypertension due to vasculitis [letter]. Clin Nephrol 1994; 42:139-140.
222. Katschinski DM, Jelkmann W, Wiedemann GJ, Mentzel M, Mulkerin DL, Touhidi R, Robins HI. Dynamic changes in serum erythropoietin levels in solid tumour patients undergoing 41.8_C whole body hyperthermia and=or chemotherapy. Int J Hyperthermia 1997; 13:563-569.
223. Shamseddine A, Medawar W, Seoud M, Ibrahim K, Habbal Z, Kahwaji S, Khalil A. The relationship between serum levels of erythropoietin (EPO) and insulin-like growth factor-1 (ILGF-1) and hematocrit (HCT) in breast cancer patients receiving non-nephrotoxic chemotherapy. Eur J Gynaecol Oncol 1998; 19:591-593.
224. Shamseddine A, Khalil A, Seoud M, Kahwaji S, Taher A, Bizri AR, Medawar W. The relation between erythropoietin, hematocrit and hemoglobin in breast cancer patients on non-nephrotoxic chemotherapy. Eur J Gynaecol Oncol 1998; 19:577-579.
225. Dowd MD, Morgan ER, Langman CB, Murphy S. Serum erythropoietin levels in children with leukemia. Med Pediatr Oncol 1997; 28:259-267.
226. Lechner W, Artner Dworzak E, Solder E, Sachsenmaier M, Kolle D, Moncayo H, Reitsamer R. Influence on erythropoietin levels of treatment with cisplatinum-endoxan. Arch Gynecol Obstet 1992; 252:49-53.
227. Saijo Y, Nakai Y, Saito J, Sugawara S, Suzuki S, Numata Y, Motomiya M. Changes in serum erythropoietin levels during chemotherapy for lung cancer. Chemotherapy 1992; 38:281-285.
228. Onat H, Inanc SE, Dalay N, Karaloglu D, Erturk N, Yasasever V. Effect of cisplatin on erythropoietin and iron changes [letter]. Eur J Cancer 1993; 29A:777.
229. Canaparo R, Casale F, Muntoni E, Zara GP, Della PC, Berno E, Pons N, Fornari G, Eandi M. Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy. Br J Clin Pharmacol 2000; 50:146-153.
230. Pedain C, Herrero J, Kunzel W. Serum erythropoietin levels in ovarian cancer patients receiving chemotherapy. Eur J Obstet Gynecol Reprod Biol 2001; 98:224-230.
231. Orhan B, Yalcin S, Evrensel T, Kurt E, Manavoglu O, Erbas T. Does cisplatin stimulate erythropoietin secretion from the peritubular cells of the kidney? [letter]. Clin Nephrol 1998; 50:202-203.
232. Hasegawa I, Tanaka K. Serum erythropoietin levels in gynecologic cancer patients during cisplatin combination chemotherapy. Gynecol Oncol 1992; 46:65-68.
233. Smith DH, Goldwasser E, Vokes EE. Serum immunoerythropoietin levels in patients with cancer receiving cisplatinbased chemotherapy. Cancer 1991; 68:1101-1105.
234. Bray GL, Reaman GH. Erythropoietin deficiency: a complication of cisplatin therapy and its treatment with recombinant human erythropoietin. Am J Pediatr Hematol Oncol 1991; 13:426-430.
235. Cazzola M, Mercuriali F, Brugnara C. Use of recombinant human erythropoietin outside the setting of uremia. Blood 1997; 89:4248-4267.
236. Fischl M, Galpin JE, Levine JD, Groopman JE, Henry DH, Kennedy P, Miles S, Robbins W, Starrett B, Zalusky R, Abels RI, Tsai HC, Rudnick SA. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med 1990; 322:1488-1493.
237. Pincus T, Olsen NJ, Russell IJ, Wolfe F, Harris ER, Schnitzer TJ, Boccagno JA, Krantz SB. Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am J Med 1990; 89:161-168.
238. Ludwig H, Fritz E, Leitgeb C, Pecherstorfer M, Samonigg L, Schuster J. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 1994; 84:1056-1063.
239. Cazzola M, Ponchio L, Pedrotti C, Farina G, Cerani P, Lucotti C, Novella A, Rovati A, Bergamaschi G, Beguin Y. Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy. Haematologica 1996; 81:434-441.
240. Oberhoff C, Neri B, Amadori D, Petry KU, Gamucci T, Rebmann U, Nowrousian MR, Voigtmann R, Monfardini S, Armand JP, Herrmann R, Netter-Pinon J, Tubiana-Mathieu N, Zwierzina H. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study [see comments]. Ann Oncol 1998; 9:255-260.
241. ten Bokkel Huinink WW, de Swart CA, van Toorn DW, Morack G, Breed WP, Hillen HF, van der Hoeven JJ, Reed NS, Fairlamb DJ, Chan SY, Godfrey KA, Kristensen GB, van Tinteren H, Ehmer B. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy [see comments]. Med Oncol 1998; 15:174-182.
242. Charuruks N, Voravud N, Limpanasithikul W. Ratio of baseline erythropoietin (EPO) level and corrected reticulocyte count as an indicator for a favourable response to recombinant human erythropoietin (rhEPO) therapy in anaemic cancer patients. J Clin Lab Anal 2001; 15:260-266.
243. Leon MP, Jimenez MM, Barona ZP, Riol DM, Castro PL, Sierrasesumaga AL. Recombinant human erythropoietin in anemia associated with pediatric cancer: study of the identification of predictors of response. An Esp Pediatr 1998; 49:17-22.